Chronic Traumatic Encephalopathy

Proceedings of the Boston University Alzheimer's Disease Center Conference

Authors:

Brand: Elsevier

ISBN: 9780323544252

PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 30 DAYS

476.22 zł

404.79 zł Save 71.43 zł Tax included

Lowest price within 30 days before promotion: 404.79 zł

Quantity

Available in 4-6 weeks

Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Get a thorough, expert overview of the many key facets of chronic traumatic encephalopathy (CTE) with this concise, practical resource by Drs. Andrew E. Budson, Ann C. McKee, Robert C. Cantu, and Robert A. Stern. This easy-to-read reference is based on lectures from Boston Universitys Alzheimers Disease Centers November 2016 two-day conference on CTE.

Product Details

Brand Elsevier

Reference 59356

EAN13 9780323544252

ISBN 9780323544252

Data sheet

Publication date: 2017
Issue number: 1
Cover: hard cover
Pages count: 198
Dimensions (mm): 191 x 235
Weight (g): 570

1 History of Concussion and Chronic Traumatic Encephalopathy
2 Pathology of Chronic Traumatic Encephalopathy
3 Chronic Traumatic Encephalopathy: Clinical Presentation and Diagnostic Criteria
4 Biomechanics of Head Trauma
5 Mechanisms of Concussion, Traumatic Brain Injury, and Chronic Traumatic Encephalopathy: Acute and Chronic Effects of Blast Exposure
6 Family Panel Discussion
7 Genetics of Chronic Traumatic Encephalopathy
8 Comorbid Pathology in Chronic Traumatic Encephalopathy
9 Differential Diagnosis and Treatment of Chronic Traumatic Encephalopathy
10 Fluid Biomarkers for Mild Traumatic Brain Injury and Chronic Traumatic Encephalopathy
11 Toward Imaging Chronic Traumatic Encephalopathy
12 From Chronic Traumatic Encephalopathy Biomarkers to Therapeutics: What We Need to Know to Design Clinical Trials
13 Athlete Panel Discussion